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Summary
 
Ceramides are intramembrane diffusible mediators involved in transducing signals originated
from a variety of cell surface receptors. Different adaptive and differentiative cellular responses,
including apoptotic cell death, use ceramide-mediated pathways as an essential part of the pro-
gram. Here, we show that human dendritic cells respond to CD40 ligand, as well as to tumor
necrosis factor-
 
a
 
 and IL-1
 
b
 
, with intracellular ceramide accumulation, as they are induced to
differentiate. Dendritic cells down-modulate their capacity to take up soluble antigens in re-
sponse to exogenously added or endogenously produced ceramides. This is followed by an im-
pairment in presenting soluble antigens to specific T cell clones, while cell viability and the ca-
pacity to stimulate allogeneic responses or to present immunogenic peptides is fully preserved.
Thus, ceramide-mediated pathways initiated by different cytokines can actively modulate pro-
fessional antigen-presenting cell function and antigen-specific immune responses.
 
D
 
endritic cells (DCs) represent key players in the im-
mune response (1). They capture and process antigens
in nonlymphoid tissues, then move into T cell–dependent
areas of secondary lymphoid organs to prime naive T cells
and initiate the immune response (2). Along this process,
DCs lose antigen-capturing ability as they differentiate into
mature, fully stimulatory antigen-presenting cells (APCs)
(3). The recent establishment of an in vitro system that al-
lows human DCs to be mantained in culture preserving
their immature phenotype, i.e., efficient antigen uptake
and processing, has revealed a unique tool to gain insights
into the basic mechanisms governing the differentiation of
DCs (4). Evidence has been provided, in fact, that tumor
necrosis-factor-
 
a
 
 (TNF-
 
a
 
) (via the p55 TNF-R1), IL-1
 
b
 
,
CD40 ligand (CD40L), and bacterial lipopolysaccaride (LPS)
can promote DC differentiation in vitro, resulting in irre-
versible structural and functional changes associated with a
mature DC phenotype, including downregulation of anti-
gen uptake and processing capacity (5). However, little is
known about the intracellular signals that are responsible for
mediating these changes in DCs after cytokines or bacterial
products exposure.
Sphingomyelin breakdown by sphingomyelinases, with
resulting ceramide release, is a major signaling event that
follows both TNF-R1 and IL-1
 
b
 
 receptor engagement by
their respective ligands (6, 7). Ceramide diffuses within mem-
branes activating downstream effectors, including different
protein kinases and phosphatases, eventually leading to a
variety of adaptive and differentiative cellular responses (8–10).
Intriguingly, LPS, also a potent inducer of DC differentia-
tion (5), mimics many of the cellular responses initiated by
TNF-
 
a
 
 and IL-1
 
b
 
, without inducing sphingomyelin hydrol-
ysis but likely becouse of its structural analogy with ceram-
ide itself (11, 12). Therefore, we investigated whether some
of the differentiative changes induced in DCs by inflama-
tory cytokines and LPS could be mediated by ceramides.
 
Materials and Methods
 
In Vitro Culture of Human DCs.
 
PBMCs obtained by standard
Ficoll–Paque method (Organon Teknika, Durham, NC) were
separated on multistep Percoll gradients (Pharmacia Fine Chemi-
cals, Uppsala, Sweden) and the light density fraction from the
 
42.5–50% interface was recovered and depleted of CD19
 
1
 
 and
CD2
 
1
 
 cells using magnetic beads coated with specific antibodies
(Dynal, Oslo, Norway). The remaining cells were cultured in
 
RPMI-1640 supplemented with 2 mM 
 
l
 
-glutamine, 1% nones-
sential aminoacids, 1% pyruvate, 50 
 
m
 
g/ml kanamicin, 5 
 
3
 
 10
 
2
 
5
 
M 2-ME (GIBCO BRL, Gaithersburg, MD) 
 
1
 
 10% FCS (Hy-
clone Laboratories, Inc., Logan, UT) in the presence of 50 ng/ml
GM–CSF and 1000 U/ml IL-4 (provided by Dr. A. Lanzavec-
chia, Basel Institute for Immunology, Switzerland). Cultured
DCs were routinely 
 
.
 
90% CD1
 
1
 
, HLA-DR
 
1
 
, CD14
 
2
 
, and were
used after 5–7 d of culture.
 
Ceramide Mass Measurement Assay.
 
After stimulation, lipids were
extracted and then incubated with 
 
Escherichia coli
 
 diacylglycerol
kinase. Ceramide phosphate was then isolated by TLC using
CHCl
 
3
 
/CH
 
3
 
OH/CH
 
3
 
COOH (65:15:5) as solvent (13, 14). Au-
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thentic ceramide-1-phosphate was identified by autoradiography
at Rf 0.25. Quantitative results for ceramide production are ex-
pressed as pmol ceramide-1-phosphate/10
 
6
 
 cells.
 
Endocytosis and Antigen Presentation Assays.
 
2 
 
3
 
 10
 
5
 
 DCs were
resuspended in 200 
 
m
 
l RPMI buffered with 25 mM Hepes 
 
1
 
 10%
FCS. C2-ceramide and C2-dihydroceramide (Sigma Immuno-
chemicals, St. Louis, MO) were reconstituted in EtOH at 15 mM
and stored at 
 
2
 
20
 
8
 
C until use. Diacylglycerol was purchased
from Amersham (Buckingham, England). Lucifer yellow (LY),
FITC–dextran (DX) (Molecular Probes, Inc., Eugene, OR), or
HRP (Sigma Immunochemicals) were reconstituted in PBS,
stored at 4
 
8
 
C, and spun in a microfuge before use to eliminate ag-
gregates. To quantify LY and FITC–DX, cells were washed four
times with cold PBS containing 1% FCS and 0.01% NaN
 
3
 
 and
analyzed on a FACScan
 
Ò
 
 (Becton Dickinson, Mountain View, CA),
using propidium iodide to exclude dead cells. For horseradish
peroxidase (HRP) quantification, cells were washed four times as
above then four times with PBS alone with one tube change, lysed
with 0.05% Triton X-100 in 10 mM Tris buffer pH 7.4 for 30
min, and the enzyme activity of the lysate was measured using
O-phenilendiamine and H
 
2
 
O
 
2
 
 as substrates with reference to a
standard curve. Tetanus toxoid (TT)-specific T cell clones KS140
and KB24 and TT peptide P2 (residues 830–843) were provided
by Dr. A. Lanzavecchia. TT antigen was purchased from Con-
naught (Ontario, Canada).
For antigen presentation assays, 4 
 
3
 
 10
 
4
 
 T cells were cultured
with 10
 
4
 
 irradiated DCs in 200 
 
m
 
l RPMI with 10% FCS in flat-
bottomed microplates. [
 
3
 
H]thymidine incorporation was mea-
sured at day 2. For MLR, 1.5 
 
3
 
 10
 
5
 
 responding cells from allogeneic
adult PBMCs were cultured with different numbers of irradiated
DCs. [
 
3
 
H]thymidine incorporation was measured at day 5. 
 
Pari-
etaria judaica
 
 pollen (Allergon, Angelholm, Sweden) was extracted
with bicarbonate buffer 0.125 M pH 8. PjE-specific clone P6.2
was isolated from an atopic patient (15).
 
DNA Labeling and Flow Cytometry Analysis.
 
2 
 
3 
 
10
 
5
 
 DCs were
treated in 200 
 
m
 
l RPMI 10% FCS with 80 
 
m
 
M C2-ceramide for
10 min on ice, then for 1 h at 37
 
8
 
C. After incubation, cells were
washed and left in culture for 48 h. Cells were then recovered
and processed for propidium iodide staining and FACS
 
Ò
 
 analysis
as previously described (13).
 
Other Reagents.
 
Supernatant from J558L cells stably express-
ing a chimeric mCD40L–mCD8
 
a
 
 construct, provided by Dr. P.
Lane, (Basel Institute for Immunology) was used as a source of
CD40L. Recombinant human TNF-
 
a
 
 with R32W and S86T
substitutions (TNF-R1 specific) and TNF-
 
a
 
 with D143N and
A145R substitutions (TNF-R2 specific) were provided by Drs.
W. Lesslauer and H. Loetscher (Hoffman La Roche, Ltd., Basel,
Switzerland). IL-1
 
b
 
 was provided by Dr. L. Melli (IRIS, Siena,
Italy).
 
Results and Discussion
 
Cytokines that Induce Maturation, Signal Ceramide Accumu-
lation in DCs.
 
IL-1
 
b
 
 and TNF-
 
a
 
 have been shown to in-
duce transient ceramide accumulation in tumor cell lines
(16, 17). It was not known whether CD40, like other TNF
receptor family members such as TNF-R1 p55, Fas/APO-1,
or NGF-R p75 (13, 16, 18), also signaled through ceramide
generation. Therefore, we investigated whether cross-link-
ing of CD40 was able to induce ceramide accumulation in
cultured immature DCs. Fig. 1 shows that CD40L, as well
as IL-1
 
b
 
 and TNF-
 
a
 
, engaging TNF-R1 p55 but not
TNF-R2 p75, were all potent inducers of ceramide gener-
ation in cultured DCs. Because CD40L, IL-1
 
b
 
, and TNF-
 
a
 
trigger in vitro maturation of DCs (5), as does LPS, which
is structurally analogous to ceramide itself (11), these results
raised the possibility that a common ceramide-mediated
pathway, mimicked by LPS, could be responsible for some
of the functional changes observed during in vitro matura-
tion of DCs.
 
Ceramides Down-modulate Macromolecule Uptake by DCs.
 
To test this hypothesis directly, we investigated whether
exposure to exogenous cell-permeant C2-ceramide could
down-modulate DC antigen uptake ability. DCs capture
antigen either via macropinocytosis, a cytoskeleton-depen-
dent type of fluid phase endocytosis initiated by membrane
ruffling and formation of large vesicles, or receptor-medi-
ated endocytosis through Fc
 
g
 
 and mannose receptors (5).
As shown in Fig. 2, C2-ceramide could inhibit the uptake
of three different classical endocytosis markers and their
time-dependent accumulation into DCs. Both macropi-
nocytosis, as assessed by LY and FITC-DX, and receptor-
mediated endocytosis, as assessed by limiting amounts of
HRP, were significantly affected. Comparable results were
also obtained using C6-ceramide, a longer acyl chain cera-
mide analogue (data not shown). By contrast, C2-dihydro-
ceramide, a structural analogue of C2-ceramide that lacks a
double bond at the 4–5 position in the sphingoid base, was
ineffective. Similarly, exposure to other diffusible signal-
transducing lipid mediators such as diacylglycerol, did not
affect macromolecule uptake ability of DCs (Fig. 2, 
 
A
 
, 
 
C
 
, 
 
E
 
).
We then tested whether the endogenous production of
ceramide would result in a similar inhibition of the endocytic
Figure 1. Ceramide production in DCs following CD40L, IL-1b (A),
and TNF-a exposure (B). DCs were isolated and cultured as described (4),
then left untreated (A, open circles) or stimulated for the indicated times
with proper amounts of soluble CD40L (31) (A, closed circles), 104 U/ml
IL-1b (A, closed triangles), 200 ng/ml TNF-a (B, closed triangles), 200 ng/
ml TNF-a with R32W and S86T substitutions (TNF-R1 specific) (B,
open circles), and 200 ng/ml TNF-a with D143N and A145R substitutions
(TNF-R2 specific) (B, closed circles) (32). Lipids were extracted and incu-
bated with E. coli diacylglycerol kinase for ceramide quantitation (13).
Mean data 6 one SD were obtained from three experiments from three
donors. 
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ability of DCs. Exposure of cultured DCs to exogenous
sphingomyelinase, which results in intracellular ceramide
accumulation (data not shown), also induced a dose-depen-
dent inhibition of HRP uptake (Fig. 3 
 
A
 
) and substantially
retarded its time-dependent accumulation (Fig. 3 
 
B
 
). Taken
together, these results indicated that ceramide could specif-
ically mediate inhibition of macromolecules uptake by DCs.
 
Ceramides Down-modulate Soluble Antigen Presentation by
DCs.
 
Cultured DCs are extremely efficient at presenting
soluble antigen to specific T cells (2). In vitro maturation of
DCs promoted by short term exposure to TNF-
 
a
 
 results in
a severalfold decrease of the antigen presentation capacity,
associated with an increase in T cell stimulatory ability (4).
Therefore, we tested whether ceramide could be sufficient
for effectively modulating antigen presentation to T cells
by using two different soluble antigens, TT and a soluble
extract of 
 
P. judaica
 
 pollen (PjE). Cultured DCs were ex-
posed to C2-ceramide and then pulsed with TT or PjE,
before being used to challenge antigen-specific T cell clones
(15, 19). Fig. 4 shows that C2-ceramide induced a 
 
z
 
50-
fold reduction in the ability of DCs to present PjE, and
 
z
 
100-fold reduction in the ability to present TT to their
respective T cell clones (Fig. 4, 
 
A and B). By contrast, DCs
treated with C2-ceramide were at least as efficient as un-
treated DCs in presenting nonprocessed antigen, i.e., in
presenting an immunogenic TT peptide to the same TT-
specific T cell clone (Fig 4 C). Ceramide analogue C2-dihy-
droceramide  was ineffective in blocking the response to
soluble antigens (Figs. 4, A, B, and C).
C2-ceramide is known to induce apoptotic cell death when
administered to hemopoietic tumor cell lines or to in vivo-
activated primary lymphoid cells within 6–12 h (20–22).
Therefore, we checked whether the observed changes in
antigen-processing capacity were due to loss of cell viabil-
ity. C2-ceramide–treated DCs cultured for as long as 48 h
excluded Trypan blue, displayed normal morphology, and
Figure 2. C2-ceramide inhibits both fluid phase and mannose receptor
mediated endocytosis by DCs. (A, C, E) 2 3 105 DCs were incubated
with different concentrations of C2-ceramide (open circles), C2-dihydroce-
ramide (closed circles), or diacylglycerol (closed triangles) for 10 min on ice,
then transferred at 378C and LY (1 mg/ml) (A), FITC–DX (1 mg/ml)
(C), or HRP (0.1 mg/ml) (E) were added for 30 min. Results are ex-
pressed as percent of maximum uptake. The background (cells pulsed at
08C) was less than 1% of the uptake at 378C in all the experiments. (B, D,
F) 2 3 105 DCs were pretreated with 80 mM C2-ceramide (open circles) or
medium (closed squares) for 10 min on ice, then transferred at 378C and LY
(B), FITC–DX (D) or HRP (F) accumulation was measured at different
times. Results are expressed as mean fluorescence intensity (B, D) or as
amount of cell-associated HRP (F). Comparable results were obtained us-
ing five different DC preparations. The vehicle did not affect endocytosis
(data not shown).
Figure 3. Endogenously produced ceramide inhibits endocytosis by
DCs. 2 3 105 DCs were incubated with Streptomyces sp. SMase (open cir-
cles) at different concentrations (A) or at 0.1 U/ml (B) for 1 h at 378C,
then HRP was added at the final concentration of 1 mg/ml for 30 min
(A) or for different times (B). The results are expressed as percentage of
maximum HRP uptake (A) or as the amount of cell associated HRP and
compared with untreated cells (closed squares) (B).2414 Ceramides Modulate Antigen Presentation by Dendritic Cells
did not show any DNA fragmentation by propidium iodide
staining and FACSÒ analysis (Fig. 4, D and E). Moreover,
C2-ceramide treatment did not affect the ability of DCs to
stimulate allogeneic T cells (Fig. 4 F).
Finally, we investigated whether the endogenous produc-
tion of ceramide would affect the ability of DCs to present
soluble antigen to T cells. Cultured DCs were treated with
exogenous sphingomyelinase before being pulsed with TT,
or with a TT peptide, and used to challenge a TT-specific
T cell clone. Fig. 5 shows that endogenous ceramide pro-
duction almost completely prevented presentation of solu-
ble TT antigen, but had no inhibitory effect on TT peptide
presentation by DCs, to the same TT-specific T cell clone.
In this paper, we provide evidence that ceramides inhibit
the antigen-capturing ability of cultured DCs, thereby sug-
gesting a common molecular basis for CD40L, TNF-a,
and IL-1b, or bacterial products such as LPS, to down-
modulate antigen presentation by professional APC (5). In
fact, we show that CD40L, as well as TNF-a or IL-1b,
were all strong inducers of ceramide accumulation in DCs.
Ceramides may specifically control antigen capturing and
processing by DCs, as other cytokine-mediated differentia-
tion events, i.e., upregulation of LFA1, B7-1, ICAM-1,
and MHC molecules, were not consistently affected by ce-
ramide exposure (data not shown). Accordingly, the en-
hanced immunostimulatory ability of mature DCs could
not be promoted by exogenous ceramides, suggesting that
additional intracellular mediators participate in the matura-
tive process. Importantly, specific immunoefficiency of DCs
can be inhibited without affecting cell viability or the abil-
ity to present nonprocessed antigen.
A possible explanation for these findings may reside in
the capacity of endogenously released ceramides to inter-
fere with vesicular trafficking. In fact, ceramides have been
shown to directly inhibit endocytosis (23) and glycoprotein
transport through the Golgi complex in CHO cells (24).
Perturbing anterograde transport through the Golgi may
prevent newly synthesized MHC class II molecules to reach
endosomal compartments to be loaded with peptides de-
Figure 4. C2-ceramide inhib-
its presentation of native antigen
but does not inhibit presentation
of peptide and alloantigens. (A)
Proliferative response of CD41
T cell clone P6.2 to different
concentrations of PjE. DCs were
left untreated (open squares), pre-
treated with 80 mM C2-ceramide
(closed circles), or with C2-dihy-
droceramide (open circles). (B)
Proliferative response of CD41
T cell clone KB24 to different
concentrations of soluble TT. DCs
were left untreated (open squares),
pretreated with 80 mM C2-cer-
amide (closed circles), or with C2-
dihydroceramide (open circles). (C)
Proliferative response of CD41
T cell clone KS140 to 1 mg/ml
of soluble TT and 10 ng/ml TT
peptide P2 (residues 830–843)
(19). DCs were left untreated
(open bars), pretreated with 80
mM C2-ceramide (closed bars), or
with C2-dihydroceramide (hatched
bars). In all experiments, DCs were
pulsed  for 1 h with antigen,
washed, irradiated, and mixed at
1:4 ratio with T cells. [3H]thy-
midine incorporation (1 mCi/
well, sp act 5 Ci/mMol) was measured on day 2 and results are expressed as mean of triplicate cultures 6 one SD. (D and E) FACSÒ histograms of pro-
pidium iodide–stained nuclei from untreated DCs (D) or DCs treated with 80 mM C2-ceramide and then cultured for 48 h (E). (F) Adult PBMCs were
cultured with different number of allogeneic DCs treated with 80 mM C2-ceramide (closed circles) or left untreated (open squares). [3H]thymidine incorpo-
ration were measured after 5 d and results are expressed as mean of triplicate cultures 6 one SD.
Figure 5. Endogenous ceramide in-
hibits presentation of soluble TT antigen
but not of TT peptides by DCs. Prolif-
erative response of CD41 T cell clone
KS140 to 1 mg/ml of soluble TT and 10
ng/ml TT peptide P2. DCs were pre-
treated for 2 h with 0.1 U/ml Streptomy-
ces sp. SMase (closed bars), or left un-
treated (open bars), pulsed for 1 h with
antigen or peptide, then mixed at 1:4 ra-
tio with T cells. [3H]thymidine incorpo-
ration was measured on day 2. Results
are expressed as mean of triplicate cul-
tures 6 one SD.2415 Sallusto et al. Brief Definitive Report
rived from hydrolyzed antigen. Interestingly, the fungal
antibiotic brefeldin A (BFA), a classic inhibitor of both
endogenous and exogenous antigen processing and presen-
tation (25, 26), which causes disassembly of the Golgi ap-
paratus (27) and its fusion with the ER and with early en-
dosomes (28, 29), also triggers sphingomyelin hydrolysis
resulting in ceramide production (30). Therefore, it is likely
that the capacity of BFA to modulate antigen presentation
is mediated by endogenously released ceramide.
Ceramides are emerging as intramembrane messengers
involved in a variety of cellular adaptive and differentiative
responses. Here, we provide evidence for a novel important
function of ceramides in highly specialized cells such as DCs,
which is modulation of soluble antigen presentation. More-
over, our data suggest that the capacity of ceramides to per-
turb intracellular membrane trafficking may be exploited
by extracellular ligands able to trigger sphingomyelin hy-
drolysis, or by bacterial products that mimic ceramide, such
as LPS, in order to regulate professional APC function and
antigen-specific immune responses.
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